天辰生物医药递表港交所 国金证券（香港）为保荐人

Core Viewpoint - Tianchen Biopharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) as its sole sponsor [1] Company Overview - Tianchen Biopharmaceutical has developed a comprehensive pipeline of biopharmaceutical products targeting various medical fields, including otolaryngology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune diseases [1] - The company has two main proprietary research and development platforms: a high-affinity antibody discovery platform and a dual-functional antibody development platform [1] Market Potential - The global market for autoimmune disease drugs and allergic disease drugs is expected to continue growing, with the Chinese market showing particularly rapid growth [1] Key Products - The core product LP-003 is a next-generation anti-IgE antibody aimed at treating allergic diseases, leading the clinical development progress among similar drugs globally [1] - Another key product, LP-005, is a dual-functional antibody fusion protein targeting C5 and C3b complement, intended for the treatment of various autoimmune diseases, including paroxysmal nocturnal hemoglobinuria and complement-mediated kidney diseases [1] Clinical Development Status - Both LP-003 and LP-005 have received IND approval from the CDE and have entered clinical development stages [1] - LP-003 has obtained multiple IND approvals for indications in China and is currently undergoing Phase III clinical trials, with plans to submit a BLA by the third quarter of 2026 or earlier [1] - LP-005 is in a Phase II clinical trial in China and plans to initiate a Phase II clinical trial targeting complement-mediated kidney diseases [1] - The company is also developing other candidate drugs, including LP-00A, LP-00C, and LP-00D [1]